specialti pharma top-read note august
strateg option opioid litig meet drove focu
includ link top-read notes/report publish august proxi
see greatest investor interest top note rank order read
took top spot focu high strateg option rx busi ii outlook
core chca busi opioid litig also recur theme throughout month
sever updat drive volatil name includ teva final host meet
last month also top area focu investor
notes/report august top rank order read activ
link remaind page
see four option rx busi includ potenti creativ combin aug
teva volatil remain lower target five takeaway call cross-read aug
detail path forward post manag meet lot focu near-term aug
still expect acquisit close out-year ep concern persist aug
industri specialti pharma focus next week manag meet
industri specialti pharma focus next week meet opioid jnj/ok trial
feedback/push-back note analyz rx sale option address pro forma model aug
industri specialti pharma focus next week busi ep week one line set-up
 execut mix shift occur leverage/opioid overhang weigh heavili aug
industri specialti pharma short interest opioid concern drive si higher closer look
industri specialti pharma focus next week focu opioid ok decis
monday incom feedback aug
price prior trade day market close estimate unless otherwis note
valu usd unless otherwis note
specialti pharma top-read note august
publish note august order read
stori move right direct thought post updat manag
industri specialti pharma short interest sever larg move ahead closer look
aug
look long road ahead lower target aug
strateg valu pipeline/busi develop key realiz
industri india gener cipla aurobindo lupin gx read take cross-read
coverag late week earn call aug
zilretta sale continu ramp full-year guidanc begin look conserv
take weak debat perspect speak
agrx surpris stori remain on-track ahead key adcom/pdufa
formulari momentum build groundwork still laid chang
kmph licens agreement still ahead despit delay time thought path
aug
stori on-track catalyst-heavi ou partnership discuss advanc
continu xhanc progress encourag come strong underli
aqst stori well track liberv data come fall kol day aug
deliv solid thought weak post manag call aug
xyrem continu drive come conserv guid also catalyst-
focu remain high gvoke pdufa commerci launch plan
base busi pressur key specialti program continu move
report bring modest beat detail faq color
results/outlook focu remain deal close aug
specialti pharma top-read note august
deliv beat reaffirm full year outlook momentum continu
 symphoni data juli in-lin expect show strong
announc deal cavion lead product expand focu
 result larg line full year re-affirmed cc et
 fda approv harmoni wakix pitolis surpris conserv
xyrem guid absorb competit impact aug
 settlement principl reach resolv track case ohio mdl
teva teva report modest beat re-affirmed guid come announc
cfo departur question aug
 miss come manag shake-up anticip share
result somewhat mix outlook unchang rx plan still unclear
focu call aug
specialti pharma top-read note august
